Review Article
Therapies with Emerging Evidence of Efficacy: Avotermin for the Improvement of Scarring
Table 2
Agents in development for the reduction of dermal scarring.
| Agents in preclinical development for the reduction of dermal scarring |
| Company | Agent | Status |
| First String | polypeptide -connexin | Preclinical | Phylogica | PYC-35B | Preclinical | Sirnaomics | STP-705 | Preclinical |
| Agents in clinical development for the reduction of dermal scarring |
| Capstone Therapeutics | AZX-100: 24 amino acid peptide analogue of heat shock protein 20, an intracellular actin-relaxing molecule | Phase II | CoDa Therapeutics | Nexagon: an anti-connexin oligonucleotide, shown to increase rate of wound healing | Phase I | Excaliard | antisense inhibitors of Smads, Connective Tissue Growth Factor | Phase II | Renovo | Ilodecakin (Prevascar): recombinant human interleukin 10 | Phase II | Avotermin (Juvista): recombinant human TGF3 | Phase III |
|
|